Background: Data from the literature has documented a remarkable immune-modulating role of prolactin. Previous evaluations of prolactin levels in patients with multiple sclerosis (MS), disease of autoimmune origin, showed conflicting results. Thus, to clarify the impact of prolactin on MS pathology we decided to assess prolactin levels in plasma and cerebrospinal fluid in naïve to treatment subjects with newly diagnosed MS.
Material and methods: A total number of 83 individuals were included: 41 patients with MS (30 females/11 males) and 42 age-matched controls (36 females/6 males). All MS subjects were newly diagnosed and they were without any treatment at the time of taking the samples of blood and cerebrospinal fluid. Prolactin was determined both in plasma and cerebrospinal fluid, and cytokines (TNF-alpha, IL-6, IL-10) were evaluated in plasma in all subjects.
Results: Prolactin levels in plasma were found to be markedly lower in MS patient when compared to those of the controls (7.64±5.99 ng/ml vs 10.12±6.76 ng/ml; P<0.05). These results correspond with concentration of prolactin measured in cerebrospinal fluid as in MS individuals prolactin was significantly decreased (2.84±0.35 ng/ml vs 3.42±0.89 ng/ml; P<0.05). The comparison of cytokines levels revealed no differences between the examined groups. A positive correlation between prolactin concentration in plasma and TNF-alpha levels was found in MS subjects.
Conclusion: Decreased levels of prolactin may reflect disturbed pituitary activity as well as disrupt immunological system regulation at the early stage of multiple sclerosis.
Acknowledgment: The study was supported with CMKP grant no.501-1-31-22-2015.
20 May 2017 - 23 May 2017